www.nasdaq.com

www.nasdaq.com
Share

www.nasdaq.com

 •  October 12

Seattle Genetics ( SGEN ) launched to its highest point in four months Wednesday after announcing a series of cancer drug trials with Dow component Merck ( MRK ) and Japanese drugmaker Astellas Pharma. [ibd-display-video id=2350024 width=50 float=left autostart=true]By the closing bell on the stock market today , Seattle Genetics had surged 6.5% to...

www.nasdaq.com

 •  September 27

Building on Current Collaborations for Educational & Economic Research with Multi-Center Clinical Trials IRVINE, CA -- (Marketwired) -- 09/27/17 -- Cannabis Science, Inc. (OTC PINK:CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, presented an update to its African Drug Development Initiative at the Constituency...

www.nasdaq.com

 •  September 20

TOKYO, Sept 20 (Reuters) - Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments. It is the first clinical trial evaluating the drug, Intuniv, in patients aged 18 and over, the...

www.nasdaq.com

 •  September 17

(The author is a Reuters Breakingviews columnist.) HONG KONG, Sept 18 (Reuters Breakingviews) - China's drug companies could provide a boost to Big Pharma. This week's New York initial public offering of Shanghai-based Zai Lab highlights a new breed of innovative eastern drug makers specializing in treatments made from living cells known as...

www.nasdaq.com

 •  September 14

Teva Pharmaceutical Industries Limited TEVA on Monday announced that it has hired H. Lundbeck's HLUYY chief Kåre Schultz as its new CEO. The appointment ended Teva's more than six-month long search for a permanent CEO after Erez Vigodman stepped down in February this year. Israel-based Teva has been facing tough times. A challenging environment in...

www.nasdaq.com

 •  September 4

Pfizer Inc. PFE announced that the FDA has granted approval to Mylotarg for adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML). The drug also received approval to treat relapsed or refractory CD33-positive AML in adults as well as children (2 years and older). The approval was expected as the FDA's Oncologic Drug...

www.nasdaq.com

 •  August 15

Conference will engage leaders from academia and the pharmaceutical and biotechnology industries WILMINGTON, Mass.--(BUSINESS WIRE)-- Breakthroughs begin here. At the Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development, leaders from across academia and the pharmaceutical and biotechnology industries will convene...

www.nasdaq.com

 •  May 25

MUMBAI, May 25 (Reuters) - Cipla Ltd , India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period. Net loss for the firm's fourth quarter narrowed to 617.9 million rupees ($9.56 million) from a loss of 928.3 million rupees a year earlier. ...

www.nasdaq.com

 •  May 24

* Expects to launch over 30 drugs in U.S. in 2018 * Bigger launches foreseen in 2019 * Q4 net profit 3.80 bln rupees vs est. 6.45 bln rupees (Adds comments from interview with managing director) By Zeba SiddiquiMUMBAI, May 24 (Reuters) - Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this...

www.nasdaq.com

 •  May 23

(RTTNews.com) - Today's Daily Dose brings you news about the spike in Puma's shares ahead of FDA panel review; FDA approval of expanded indication of Roche's subcutaneous Actemra; FDA approval of Sanofi's Kevzara; upcoming catalyst of Spring Bank Pharma and secondary offering of GlycoMimetics. Read on... The Centers for Medicare and Medicaid...